2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
CRISPR and Gene Editing in Cancer Therapy
CRISPR and gene editing technologies have revolutionized the field of cancer therapy by providing the ability to precisely alter the genetic makeup of cancer cells. CRISPR, a tool that enables targeted gene editing, allows researchers to deactivate cancer-causing genes or correct genetic mutations that contribute to tumor growth. This technology holds the potential to not only treat cancer by directly targeting tumor cells but also to enhance the immune system’s ability to recognize and destroy cancer cells. Additionally, CRISPR could be used to modify immune cells, such as T cells, to improve their efficacy in fighting cancer. While still in the early stages, CRISPR-based therapies have shown promise in preclinical studies and clinical trials, offering new hope for more effective and personalized cancer treatments.
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China